Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib.
Journal Information
Full Title: Onco Targets Ther
Abbreviation: Onco Targets Ther
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Disclosure CV reports personal fees from Janssen, outside the submitted work. JLG reports personal fees from ASCO for Faculty for ASCO Advantage: CLL program in October 2021 and JADPRO/APSHO for being the lead author for the updated 2021 Education Module on BTK Inhibitors for APSHO (Advanced Practitioner Society for Hematology Oncology), outside the submitted work. AF received research support from Acerta (a member of the AstraZeneca Group). The authors report no other conflicts of interest in this work."
Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025